Take lots and lots and lots of pro-biotics - see my reply to the Phillips health thread today on how to make Yoghurt take the stuff while you are on the anti-biotics as well.
I found this - may be worth trying though I have no other information on taking glutamine before/after anti-biotics
"Those who use non-steroidal anti-inflammatories or antibiotics may have a special need for supplemental glutamine. Both can damage the gut lining and set up gastrointestinal disturbances or leaky gut syndrome. Fortunately, sufficient glutamine can undo the damage caused by antibiotics or NSAIDs, maintaining permeability at a healthy level. For those with any disturbance of the gut the soothing effects of glutamine taken as powder dissolved in water makes itself known quite soon after ingestion."
Also I found this below
ICAAC: Tetracycline May Protect Against C. difficile Colitis
SAN FRANSICO, Sept. 28 -- Though antibiotic exposure typically increases the risk of Clostridium difficile colitis, tetracycline may protect against it, researchers reported here
Tetracycline decreased the risk C. difficile colitis (odds ratio [OR] 0.6, (95% confidence interval [CI] 0.5 to 0.9) while other antibiotics, particularly imipenem, raised the risk, according to a case-control study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in an oral session.
Antibiotics with the highest risk included:
• imipenem (OR 3.31, CI 1.27 to 8.62, P=0.02)
• ceftazidime (OR 2.45, CI 1.48 to 4.07, P<0.01)
• clindamycin (OR 2.02, P<0.01)
• moxifloxacin (OR 1.66, P=0.03)
"In hospitals with high rates of C. difficile, physicians should consider using antibiotics with lower associated risk," said Roger Baxter, M.D., of Kaiser Permanente Northern California in Oakland.
Surprisingly, meropenem had one of the lowest associated risks (OR 1.05) though imipenem in the same class of drugs had the highest risk. The lowest risks were from tetracycline (OR: 0.6, CI: 0.5 to 0.9), doxycycline, ampicillin (often faulted as the main cause of C. difficile, noted Dr. Baxter), metronidazole, and erythromycin.
Antibiotics in the middle range with increased risk of C. difficile colitis, though not significantly so due to wide confidence intervals, included piperacillin/tazobactam, cefotetan, ampicillin/sulbactam, ceftriaxone and others.
Many earlier studies looking at risk from individual antibiotics had problems with sample size. Dr. Baxter and colleagues drew data from the Kaiser Permanente Northern California system of 54 clinics and 16 hospitals that have the advantage of consistent inter-institution infection-control standards.
The retrospective study included 696 cases seen from 2000 through 2004 of first-time C. difficile toxin assay positive infection in patients who had been exposed to antibiotics in the 60 days prior to the positive C. difficile test. Each patient was matched with eight controls (total 2,058) with the same number of days in the same hospital in the same year and quarter, same diagnosis at discharge, and who had also been exposed to antibiotics.
about half of the patients were male and the average age was 68 years for both cases and controls. However, cases had more hospitalized days (14 versus 9) and more proton pump inhibitor use (42% versus 30%).
All odds ratios were determined after controlling for prior hospitalization days, number of prior different antimicrobials and proton pump inhibitor use in a regression analysis.
Dr. Baxter cautioned that these results are somewhat different than other studies have found because of the limited power due to matching criteria. Further study will be needed to confirm the findings with regard to ceftriaxone, which has been much higher on other studies' risk findings, and the apparent protective effect of tetracylines.
Also, the newer antimicrobials like linezolid, tigecycline and daptomycin were not used frequently enough to make statistical comparisons with other agents, he said.
This study confirmed what clinicians thought was true, that broad-spectrum antibiotics increase the risk of colitis more and, therefore, are particularly going to be problematic in hospitals where there is C. difficile exposure, Dr. Baxter concluded.
Other risk factors identified in the study were older age, number of hospital days in the 60 days prior to index date, and high medical costs in the year prior to index date.
IBD and C. Difficile Make Deadly Combination
MILWAUKEE, Sept. 26 -- A Clostridium difficile infection sharply increases the risk of death for patients with underlying inflammatory bowel disease, researchers here said
People admitted to the hospital with a combination of C. difficile and either Crohn's disease or ulcerative colitis were nearly five times as likely to die as those admitted for inflammatory bowel disease alone, according to David Binion, M.D., and colleagues, at Wisconsin College of Medicine.
They were also more likely to die than patients admitted with just C. difficile associated disease, Dr. Binion and colleagues reported in the online issue of Gut.
Doctors should engage in "prudent use of antibiotics" for patients with inflammatory bowel disease to reduce the incidence of C. difficile disease, the researchers said.
Their findings came from an analysis of the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample for 2003. The sample for that year covered 37 states, 994 hospitals of all sizes and types, and more than 38 million discharges.
The investigators found that the discharge diagnosis was both C. difficile and inflammatory bowel disease in 2,804 cases, C. difficile alone in 44,400 cases, and inflammatory bowel disease alone in 77,366 cases.
A multivariate analysis showed that:
• Patients with both conditions were significantly more likely (at P<0.05) to die in the hospital than those with inflammatory bowel disease alone. The adjusted odds ratio was 4.7, with a 95% confidence interval from 2.9 to 7.9.
• Patients with both conditions were twice as likely to die as those with C. difficile associated disease alone. The adjusted odds ratio was 2.2, with a 95% confidence interval from 1.4 to 3.4, which was also significant at P<0.05.
The analysis also showed that -- compared with patients with inflammatory bowel disease alone -- those with both conditions had a longer hospital stay (3 days on average), higher hospitalization costs ($11,406 on average), and higher rates of lower GI endoscopy.
Patients with both conditions were half as likely, however, to have bowel surgery as those with inflammatory bowel disease alone (the adjusted odds ratio was 0.6), but they were much more likely to have surgery than those admitted with C. difficile alone (the odds ratio was 6.6).
Interestingly, having C. difficile and ulcerative colitis was more dangerous than C. difficile and Crohn's disease. Specifically:
• 5% of those with ulcerative colitis and coexisting C. difficile died in the hospital, compared with 3% of those with Crohn's and C. difficile. The difference was significant at P=0.01.
• Ulcerative colitis patients also had higher rates of lower GI endoscopy -- 56% versus 46.9%, which was significant at P<0.01.
• And they had higher rates of bowel surgery -- 10.4% versus 8%, which was significant at P=0.04.
Among the study's strengths, the researchers said, is the fact that it uses a large nation-wide sample. On the other hand, the researchers were unable to adjust for the severity of underlying inflammatory bowel disease.
Also, they said, it is possible that some patients classified as having inflammatory bowel disease alone also had mild C. difficile disease, but were not tested for the toxin, which would reduce the magnitude of the associations.
6 Asacol tabs/day
1 Pentasa Suppository / day
Fish oil 3/day (omega 3 only)
Multivitamin and mineral 1/day
Folic Acid 1/day
Aloe Vera 3/day
Specific Carbohydrate Diet SCD
Currently in no mans land between flare and remission